补中益气汤治疗气虚型慢性功能性便秘的疗效研究
|
摘要
目的：
观察补中益气汤治疗气虚型慢性功能性便秘的临床疗效。
方法：
采用前瞻性RCT研究方法,将符合纳入标准的78例气虚型慢性功能性便秘患者随机分为2组,对照组38例,采用乳果糖口服治疗,治疗组40例,采用补中益气汤口服治疗,治疗时间均为3个月。2组治疗前后分别进行便秘评估及相关伴随症状评分,以周排便频率达到1-2d／次的实际病例数、便秘症状积分、伴随症状积分和综合疗效积分作为疗效判定指标进行评价。2组治疗前后的结果用统计学方法分析和处理,并进行组内、组间叫的比较。
结果：
主要结局指标(大便频率)：治疗3个月后周排便频率达到1-2d／次的实际病例数分别是：对照组26例,治疗组32例,2组间比较差异无统计学意义(P>0.05)。次要结局指标(评分表)：①便秘症状评分：治疗组评分减少(9.95±2.23)分(P<0.05),对照组评分减少(8.24±2.79)分(P<0.05)；2组间比较P>0.05,2组改善便秘症状疗效无明显差异。治疗组总有效率95.0%,对照组总有效率94.7%,两组总有效率比较无明显差异(P>0.05)。②伴随症状评分：治疗组评分减少(22.83±4.91)分(P<0.05),对照组评分减少(7.68±6.28)分(P<0.05)；2组间比较P<0.05,治疗组改善便秘伴随症状疗效明显优于对照组。治疗组总有效率100.0%,对照组总有效率42.1%,治疗组总有效率明显优于对照组(P<0.05)。综合疗效评价：治疗组综合疗效总有效率为100%,对照组综合疗效总有效率为68.4%,治疗组综合疗效总有效率明显优于对照组(P<0.05)。
结论：
补中益气汤治疗气虚型慢性功能性便秘疗效确切,改善患者便秘症状可媲美乳果糖,改善患者相关伴随症状及其临床综合疗效明显优于乳果糖。
Objective
To Observe the clinical curative effect on treatment of chronic functional constipation of qi asthenia by buzhong yiqi tang.
Methods
The Prospective RCT research method was adopted in the present study and a total of78patients with chronic functional constipation of qi asthenia which were randomized into2groups. The control group (n=38) was treated with Lactulose Oral. Therapeutic group (n=40) was treated by buzhong yiqi tang. Period of treatment was3months. Constipation symptoms score and other concomitant symptoms score were evaluated before and after treatment of the2groups. The actual number of patients whose defecation frequency per week was up to1or2days per time, the score of constipation symptoms, the score of other concomitant symptoms, and the integrative score of symptoms after the treatment were recorded and evaluated. The2groups pretherapy and post-treatment consequence were compared between interclass and intragroup separately, the results were analyzed and treated using statistical methods.
Results
Main outcome index (Defecate frequency):The actual number of patients whose defecation frequency per week was up to1or2days per time after3months:control group (n=26), therapeutic group (n=32);The2groups were not statistically significant difference (P>0.05). The secondary outcome index (rating scale):①Score of constipation symptoms:therapeutic group rating reduce (9.95±2.23)(P<0.05), control group reduce (9.95±2.23)(P<0.05). Comparison among groups (P>0.05), the2groups were not statistically significant difference. Total effective rate (ORR):therapeutic group was95.0%, control group was94.7%, the2groups were not statistically significant difference in improving constipation symptoms (P>0.05).②Score of other concomitant symptoms:therapeutic group rating reduce (22.84±4.91)(P<0.05), control group reduce (7.68±6.28)(P<0.05). Comparison among groups (P<0.05), the2groups were statistically significant difference. Total effective rate (ORR):therapeutic group was100.0%but control group was42.1%, therapeutic group was better than control in improving other concomitant symptoms of constipation symptoms (P<0.05). Evaluation of comprehensive curative effect Total effective rate (ORR) of therapeutic group was100.0%, Total effective rate (ORR) of control group was68.4%, the2groups were statistically significant difference (P>0.05), therapeutic group was better than control in improving total therapeutic effect.
Conclusion
It was definite superior effect that treatment of chronic functional constipation of qi asthenia by buzhong yiqi tang. It could rival Lactulose that Buzhong yiqi tang improved constipation symptoms, and it had better effects on the other concomitant symptoms with constipation and clinical comprehensive effect than Lactulose.
观察补中益气汤治疗气虚型慢性功能性便秘的临床疗效。
方法：
采用前瞻性RCT研究方法,将符合纳入标准的78例气虚型慢性功能性便秘患者随机分为2组,对照组38例,采用乳果糖口服治疗,治疗组40例,采用补中益气汤口服治疗,治疗时间均为3个月。2组治疗前后分别进行便秘评估及相关伴随症状评分,以周排便频率达到1-2d／次的实际病例数、便秘症状积分、伴随症状积分和综合疗效积分作为疗效判定指标进行评价。2组治疗前后的结果用统计学方法分析和处理,并进行组内、组间叫的比较。
结果：
主要结局指标(大便频率)：治疗3个月后周排便频率达到1-2d／次的实际病例数分别是：对照组26例,治疗组32例,2组间比较差异无统计学意义(P>0.05)。次要结局指标(评分表)：①便秘症状评分：治疗组评分减少(9.95±2.23)分(P<0.05),对照组评分减少(8.24±2.79)分(P<0.05)；2组间比较P>0.05,2组改善便秘症状疗效无明显差异。治疗组总有效率95.0%,对照组总有效率94.7%,两组总有效率比较无明显差异(P>0.05)。②伴随症状评分：治疗组评分减少(22.83±4.91)分(P<0.05),对照组评分减少(7.68±6.28)分(P<0.05)；2组间比较P<0.05,治疗组改善便秘伴随症状疗效明显优于对照组。治疗组总有效率100.0%,对照组总有效率42.1%,治疗组总有效率明显优于对照组(P<0.05)。综合疗效评价：治疗组综合疗效总有效率为100%,对照组综合疗效总有效率为68.4%,治疗组综合疗效总有效率明显优于对照组(P<0.05)。
结论：
补中益气汤治疗气虚型慢性功能性便秘疗效确切,改善患者便秘症状可媲美乳果糖,改善患者相关伴随症状及其临床综合疗效明显优于乳果糖。
Objective
To Observe the clinical curative effect on treatment of chronic functional constipation of qi asthenia by buzhong yiqi tang.
Methods
The Prospective RCT research method was adopted in the present study and a total of78patients with chronic functional constipation of qi asthenia which were randomized into2groups. The control group (n=38) was treated with Lactulose Oral. Therapeutic group (n=40) was treated by buzhong yiqi tang. Period of treatment was3months. Constipation symptoms score and other concomitant symptoms score were evaluated before and after treatment of the2groups. The actual number of patients whose defecation frequency per week was up to1or2days per time, the score of constipation symptoms, the score of other concomitant symptoms, and the integrative score of symptoms after the treatment were recorded and evaluated. The2groups pretherapy and post-treatment consequence were compared between interclass and intragroup separately, the results were analyzed and treated using statistical methods.
Results
Main outcome index (Defecate frequency):The actual number of patients whose defecation frequency per week was up to1or2days per time after3months:control group (n=26), therapeutic group (n=32);The2groups were not statistically significant difference (P>0.05). The secondary outcome index (rating scale):①Score of constipation symptoms:therapeutic group rating reduce (9.95±2.23)(P<0.05), control group reduce (9.95±2.23)(P<0.05). Comparison among groups (P>0.05), the2groups were not statistically significant difference. Total effective rate (ORR):therapeutic group was95.0%, control group was94.7%, the2groups were not statistically significant difference in improving constipation symptoms (P>0.05).②Score of other concomitant symptoms:therapeutic group rating reduce (22.84±4.91)(P<0.05), control group reduce (7.68±6.28)(P<0.05). Comparison among groups (P<0.05), the2groups were statistically significant difference. Total effective rate (ORR):therapeutic group was100.0%but control group was42.1%, therapeutic group was better than control in improving other concomitant symptoms of constipation symptoms (P<0.05). Evaluation of comprehensive curative effect Total effective rate (ORR) of therapeutic group was100.0%, Total effective rate (ORR) of control group was68.4%, the2groups were statistically significant difference (P>0.05), therapeutic group was better than control in improving total therapeutic effect.
Conclusion
It was definite superior effect that treatment of chronic functional constipation of qi asthenia by buzhong yiqi tang. It could rival Lactulose that Buzhong yiqi tang improved constipation symptoms, and it had better effects on the other concomitant symptoms with constipation and clinical comprehensive effect than Lactulose.
引文
[1]Roberts MC, Mkan RC, Galanko JA, et al. Constipation, laxative use, and colon cancer in a North Carolina population[J]. Am J Gastroenterol,2003,98:857-864.
[2]郑松柏.重视老年人慢性功能性便秘的危害[J].老年医学与保健,2010,16(2)：77-78.
[3]American college of gastroenterology chronic constipation task force. An evidence based approach to the management of chronic constipation in north America[J]. American Journal of Gastroenterology,2005,100(SI):91-97.
[4]中华医学会外科学分会肛肠外科学组.便秘症状及疗效评估[J].中华胃肠外科杂志,2005,8(4)：355—356.
[5]危北海,陈治水,张万岱,等.胃肠疾病中医症候评分表[J].世界华人消化杂志,2004,12(11)：2701-2703.
[6]Longstreth GF, Thompson WG, Chey WD. Functional Bowel Disorders[J].In:Drossman DA eds. RomeⅢ:the functional gastrointestinal disorders. Mclean:Degnon Associates.2006,487-555.
[7]Peppas G, Alexiou VG, Mourtzoukou E, et al. Epidemiology of constipation in Europe and Oceania:a systematic review[J]. BMC Gastroenterology,2008,8(5):1-7.
[8]Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation[J]. Pharmacoeconomics,2005,23(5):461-476.
[9]Higsias PD, Johanson JF. Epidemiology of constipation in North America a systematic review[J].Am JGastroenterol,2004,99(4):750-759.
[10]李增金,于普林,时秋宽,等.北京市部分地区城乡老年人便秘的现况调查[J].中国老年学杂志,2000,20(1)：122.
[11]尉秀清,陈旻湖,等.广州市居民肠易激综合征及功能性便秘的流行病学调查[J].中内科杂志,2001,40(8)：102.
[12]郭晓峰,柯美云,等.北京地区成人慢性便秘整群、分层、随机流行病学调查及其相关因素分析[J].中华消化杂志,2002,22(10)：637-638.
[13]Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents[J]. Dis Colon Rectum,2000,43:940-943.
[14]阐志超,姚宏昌,龙治平,等.天津市成年人慢性便秘调查及相关因素分析[J].中华消化杂志,2004,24：612-614.
[15]Gottlieb SH, Schuster MM. The pathogenesis of functional constipation[J]. Gastroenterology,1986,91:428-432.
[16]Chattat R, Bazzocchi G, Balloni M, et al. Illness behavior, affective disturbance and intestinal transit time in idiopathic constipation[J]. J Psychosom Res,1997,43:95.
[17]闫翔,张毅,等.老年人功能性便秘发病机制的研究进展[J].四川医学,2004,25(8)：926-928.
[18]Lyford GL, He CL, Soffer E, et al. Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation[J]. Gut,2002, (51):496-501.
[19]董艳,陆金根,曹永清,等.慢传输型便秘病因病机研究进展[J].中国中医药咨讯.2010,2(7)： 260.
[20]Peracchi M, Basilisco G, Tagliabue R, et al. Postprandial gut peptide plasma levels in women with idiopathic slow-transit constipation[J].Scand J Gastroenterol,1999(34): 25-28.
[21]Zittel TT, Lioyd KC, Rothenhofer I, et al. Calcitonin gene-related peptide and spinal afferents partly mediate postoperative colonic ileus in the rat[J]. Surgery, 1998(123)518-527.
[22]Foxx-Orenstein A, Camilleri M, Stephens D, et al. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans [J]. Gut,2003,52(11):1555-1561.
[23]Chang FY, Lee SD, Yeh GH, et al. Rat gastrointestinal motor responses mediated via activation of neurokinin receptors[J]. J Gastroenterol Hepatol,1999,14:39-45.
[24]陈林,王建国.功能性便秘的诊断与现代治疗[J].中国药学杂志,2005,7(9)：1294-1295.
[25]袁维堂,刘金波,杨会锋.少量钡餐胃肠传输功能检查及其临床意义[J].中国医师进修杂志外科版,2006,29(4)：4-6.
[26]中华医学会消化病学分会胃肠动力学组,外科学分会结直肠肛门外科学组.中国慢性便秘的诊治指南(2007,扬州)[J].中华消化杂志,2007,27(9)：621.
[27]李可.功能性便秘的中西医治疗近况[J].中国医药导报.2009,6(3)：166-167.
[28]陈建永,潘峰,张涛,等.：蒽醌类药物致结肠黑变病的研究现状及进展[J].浙江医学,2009,31(7)：1032-1033.
[29]何凌,崔英,姜国平.功能性便秘中西医治疗近况[J].实用中西医结合临床,2004,4(2)：76-78.
[30]周永学,王倩.便秘的中西医治疗现状与硝菔通结颗粒效用分析[J].现代中医药,2004,5：11-12.
[31]张骏,周玉祥.慢性老年性便秘的中西医治疗近况[J].中国医学创新,2010,7(9)：194-196.
[32]贡鸣,李岩.精神因素对功能性便秘的影响[J].胃肠病学和肝病学杂志,2009,18(8)766-9.
[33]陈树森.陈树森医疗经验集粹[M].北京：人民军医出版社.1989,144--149.
[34]季铁铮.辨证治疗老年虚性便秘42例总结[J].中医药导报,2006,12(4)：29-30.
[35]余守雅.《金匮要略》枳术汤治疗老年习惯性便秘的临床观察[J].四川中医,2005,23(10)：72.
[36]徐中一.辨证分型治疗功能性便秘45例[J].实用中医内科杂志,2006,20(4)：387.
[37]张惠萍.老年性便秘的辨证施护及预防[J].现代中西医结合杂志,2004,13(15)：2025—2026.
[38]付照.中医辨证治疗老年性便秘[J].河南中医,2004,24(4)：77.
[39]黄绍刚,于丰彦,周福生,等.从整体观探讨功能性便秘的中医治疗[J].中国民族民间医药,2010,8(1)：83-84.
[40]张翠霞.血府逐瘀汤加减治疗顽固型便秘30例[J].河北中医,1999,21(5)：300.
[41]雷耀晨.老年便秘从瘀论治的体会[J].光明中医,2005,20(5)：51—53.
[42]李新成.四磨饮治疗慢性功能性便秘[J].湖北中医杂忠,1999,21(2)：29.
[43]翁庚民.枳术归荟丸治疗女性习惯性便秘74例[J].中国中西医结合消化杂志,2001,9(2)：104.
[44]杨波,张东焰,杨放晴.六味地黄丸治疗老年功能性便秘30例[J].医药导报,2001,20(8)：511.
[45]赵建勋.通便胶囊治疗中老年便秘196例[J].陕西中医,2006,26(9)：1067-1068.
[46]李红.不同剂量车前子对老年人功能性便秘的治疗作用[J].中国中医药信息杂志,2001,8(11)：70.
[47]王建华.中药药理与临床研究进展[M].北京：人民卫生出版社：2010,6：254-255.
[48]陈棣兰,孙晓进,任爱农,等.泰魄颗粒治疗慢性功能性便秘的研究[J].中国中西医结合消化杂志,2007,15(6)：358.
[49]王荣,胡晓阳,等.复方芸归颗粒主要药效学实验研究[J],中医药信息,2010,27(6)：84-85.
[50]王岚,彭成,郭力.附子大黄配伍对阳虚便秘动物的治疗作用及其机制研究[J].中国中西医结合消化杂志,2006,14(2)：82.
[51]邱剑锋,肖诚,康旭亮,等.养血润肠方对实验性小鼠血虚型慢性功能性便秘血清中MDA、 SOD的影响[J].中国中医基础医学杂志,2008,14(1)：39-40.
[52]邱剑锋,赖旖,罗敏,等.养血润肠方对实验性小鼠血虚型慢性功能性便秘结肠组织匀浆中MDA、SOD的影响[J].成都中医药大学学报,2011,34(1)：61-62.
[53]余学庆,李建生.中医临床疗效评价现状与思考[J].河南中医学院学报,2008,23(134)：16.
[54]周吕,柯美云主编.胃肠动力学基础与临床[M].北京：科学出版社,1999.465.
[55]Lamparelli M, Kumar D. Investigation and manag ementof constipation[J]. Clin Med, 2002,2(5):415.
[56]Frank L, Kleinman L, Farup C, et al. Psychometric Validation of a Constipation Symptom Assessment Questionnaire[J]. Scand J Gastroenterol,1999,34:870-877.
[57]Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire:new outcome measure for primarycare[J]. BMJ,1992,305:160-164.
[58]郭新峰.替代指标和中间指标及其在中医药疗效评价研究中应用价值的思考[J].中国中西医纳合杂志,2005,25(7)：585.
[59]姜小帆,邵明义.生存质量量表在中医临床诊治中的应用探析[J].江苏中医药,2008,40(11)：12.
[60]郧筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：142-143.
[61]黄绍刚,张北平,黄穗平.大肠息肉癌变过程中血管生成的表达及其与中医证候相关性的研讨[J].辽宁中医杂志,2008(35)：859-860.
[62]宋玉洁.中医脾气虚证的现代研究近况与思考[J].山东中医药人学学报,25(3)：238-240.
[61]胡学军,黄穗平,张海燕.健脾理气方对功能性消化不良患者生存质量的影响[J].实用中医药杂志,2011,27(3)：148-149.
[64]郑虎占.中药现代研究与应用[M].北京：学苑出版社,1997：101.
[65]昆山,王秀琴,董一凡.现代临床中药学[M].北京：中国中医药出版,1998：177.
[66]苗明三主编,常见中药药理与临床[M].北京：中国中医药出版社,1997,83.
[67]王运平,邱世翠,李液清,等.补中益气汤对脾虚小鼠非特异性免疫和体液免疫的影响[J].滨州医学院学报,1998,21(1)：9.
[68]齐元富.汉方药对MRSA感染的疗效[J].国外医学·中医中药分册,2000,22(2)：76.
[2]郑松柏.重视老年人慢性功能性便秘的危害[J].老年医学与保健,2010,16(2)：77-78.
[3]American college of gastroenterology chronic constipation task force. An evidence based approach to the management of chronic constipation in north America[J]. American Journal of Gastroenterology,2005,100(SI):91-97.
[4]中华医学会外科学分会肛肠外科学组.便秘症状及疗效评估[J].中华胃肠外科杂志,2005,8(4)：355—356.
[5]危北海,陈治水,张万岱,等.胃肠疾病中医症候评分表[J].世界华人消化杂志,2004,12(11)：2701-2703.
[6]Longstreth GF, Thompson WG, Chey WD. Functional Bowel Disorders[J].In:Drossman DA eds. RomeⅢ:the functional gastrointestinal disorders. Mclean:Degnon Associates.2006,487-555.
[7]Peppas G, Alexiou VG, Mourtzoukou E, et al. Epidemiology of constipation in Europe and Oceania:a systematic review[J]. BMC Gastroenterology,2008,8(5):1-7.
[8]Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation[J]. Pharmacoeconomics,2005,23(5):461-476.
[9]Higsias PD, Johanson JF. Epidemiology of constipation in North America a systematic review[J].Am JGastroenterol,2004,99(4):750-759.
[10]李增金,于普林,时秋宽,等.北京市部分地区城乡老年人便秘的现况调查[J].中国老年学杂志,2000,20(1)：122.
[11]尉秀清,陈旻湖,等.广州市居民肠易激综合征及功能性便秘的流行病学调查[J].中内科杂志,2001,40(8)：102.
[12]郭晓峰,柯美云,等.北京地区成人慢性便秘整群、分层、随机流行病学调查及其相关因素分析[J].中华消化杂志,2002,22(10)：637-638.
[13]Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents[J]. Dis Colon Rectum,2000,43:940-943.
[14]阐志超,姚宏昌,龙治平,等.天津市成年人慢性便秘调查及相关因素分析[J].中华消化杂志,2004,24：612-614.
[15]Gottlieb SH, Schuster MM. The pathogenesis of functional constipation[J]. Gastroenterology,1986,91:428-432.
[16]Chattat R, Bazzocchi G, Balloni M, et al. Illness behavior, affective disturbance and intestinal transit time in idiopathic constipation[J]. J Psychosom Res,1997,43:95.
[17]闫翔,张毅,等.老年人功能性便秘发病机制的研究进展[J].四川医学,2004,25(8)：926-928.
[18]Lyford GL, He CL, Soffer E, et al. Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation[J]. Gut,2002, (51):496-501.
[19]董艳,陆金根,曹永清,等.慢传输型便秘病因病机研究进展[J].中国中医药咨讯.2010,2(7)： 260.
[20]Peracchi M, Basilisco G, Tagliabue R, et al. Postprandial gut peptide plasma levels in women with idiopathic slow-transit constipation[J].Scand J Gastroenterol,1999(34): 25-28.
[21]Zittel TT, Lioyd KC, Rothenhofer I, et al. Calcitonin gene-related peptide and spinal afferents partly mediate postoperative colonic ileus in the rat[J]. Surgery, 1998(123)518-527.
[22]Foxx-Orenstein A, Camilleri M, Stephens D, et al. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans [J]. Gut,2003,52(11):1555-1561.
[23]Chang FY, Lee SD, Yeh GH, et al. Rat gastrointestinal motor responses mediated via activation of neurokinin receptors[J]. J Gastroenterol Hepatol,1999,14:39-45.
[24]陈林,王建国.功能性便秘的诊断与现代治疗[J].中国药学杂志,2005,7(9)：1294-1295.
[25]袁维堂,刘金波,杨会锋.少量钡餐胃肠传输功能检查及其临床意义[J].中国医师进修杂志外科版,2006,29(4)：4-6.
[26]中华医学会消化病学分会胃肠动力学组,外科学分会结直肠肛门外科学组.中国慢性便秘的诊治指南(2007,扬州)[J].中华消化杂志,2007,27(9)：621.
[27]李可.功能性便秘的中西医治疗近况[J].中国医药导报.2009,6(3)：166-167.
[28]陈建永,潘峰,张涛,等.：蒽醌类药物致结肠黑变病的研究现状及进展[J].浙江医学,2009,31(7)：1032-1033.
[29]何凌,崔英,姜国平.功能性便秘中西医治疗近况[J].实用中西医结合临床,2004,4(2)：76-78.
[30]周永学,王倩.便秘的中西医治疗现状与硝菔通结颗粒效用分析[J].现代中医药,2004,5：11-12.
[31]张骏,周玉祥.慢性老年性便秘的中西医治疗近况[J].中国医学创新,2010,7(9)：194-196.
[32]贡鸣,李岩.精神因素对功能性便秘的影响[J].胃肠病学和肝病学杂志,2009,18(8)766-9.
[33]陈树森.陈树森医疗经验集粹[M].北京：人民军医出版社.1989,144--149.
[34]季铁铮.辨证治疗老年虚性便秘42例总结[J].中医药导报,2006,12(4)：29-30.
[35]余守雅.《金匮要略》枳术汤治疗老年习惯性便秘的临床观察[J].四川中医,2005,23(10)：72.
[36]徐中一.辨证分型治疗功能性便秘45例[J].实用中医内科杂志,2006,20(4)：387.
[37]张惠萍.老年性便秘的辨证施护及预防[J].现代中西医结合杂志,2004,13(15)：2025—2026.
[38]付照.中医辨证治疗老年性便秘[J].河南中医,2004,24(4)：77.
[39]黄绍刚,于丰彦,周福生,等.从整体观探讨功能性便秘的中医治疗[J].中国民族民间医药,2010,8(1)：83-84.
[40]张翠霞.血府逐瘀汤加减治疗顽固型便秘30例[J].河北中医,1999,21(5)：300.
[41]雷耀晨.老年便秘从瘀论治的体会[J].光明中医,2005,20(5)：51—53.
[42]李新成.四磨饮治疗慢性功能性便秘[J].湖北中医杂忠,1999,21(2)：29.
[43]翁庚民.枳术归荟丸治疗女性习惯性便秘74例[J].中国中西医结合消化杂志,2001,9(2)：104.
[44]杨波,张东焰,杨放晴.六味地黄丸治疗老年功能性便秘30例[J].医药导报,2001,20(8)：511.
[45]赵建勋.通便胶囊治疗中老年便秘196例[J].陕西中医,2006,26(9)：1067-1068.
[46]李红.不同剂量车前子对老年人功能性便秘的治疗作用[J].中国中医药信息杂志,2001,8(11)：70.
[47]王建华.中药药理与临床研究进展[M].北京：人民卫生出版社：2010,6：254-255.
[48]陈棣兰,孙晓进,任爱农,等.泰魄颗粒治疗慢性功能性便秘的研究[J].中国中西医结合消化杂志,2007,15(6)：358.
[49]王荣,胡晓阳,等.复方芸归颗粒主要药效学实验研究[J],中医药信息,2010,27(6)：84-85.
[50]王岚,彭成,郭力.附子大黄配伍对阳虚便秘动物的治疗作用及其机制研究[J].中国中西医结合消化杂志,2006,14(2)：82.
[51]邱剑锋,肖诚,康旭亮,等.养血润肠方对实验性小鼠血虚型慢性功能性便秘血清中MDA、 SOD的影响[J].中国中医基础医学杂志,2008,14(1)：39-40.
[52]邱剑锋,赖旖,罗敏,等.养血润肠方对实验性小鼠血虚型慢性功能性便秘结肠组织匀浆中MDA、SOD的影响[J].成都中医药大学学报,2011,34(1)：61-62.
[53]余学庆,李建生.中医临床疗效评价现状与思考[J].河南中医学院学报,2008,23(134)：16.
[54]周吕,柯美云主编.胃肠动力学基础与临床[M].北京：科学出版社,1999.465.
[55]Lamparelli M, Kumar D. Investigation and manag ementof constipation[J]. Clin Med, 2002,2(5):415.
[56]Frank L, Kleinman L, Farup C, et al. Psychometric Validation of a Constipation Symptom Assessment Questionnaire[J]. Scand J Gastroenterol,1999,34:870-877.
[57]Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire:new outcome measure for primarycare[J]. BMJ,1992,305:160-164.
[58]郭新峰.替代指标和中间指标及其在中医药疗效评价研究中应用价值的思考[J].中国中西医纳合杂志,2005,25(7)：585.
[59]姜小帆,邵明义.生存质量量表在中医临床诊治中的应用探析[J].江苏中医药,2008,40(11)：12.
[60]郧筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：142-143.
[61]黄绍刚,张北平,黄穗平.大肠息肉癌变过程中血管生成的表达及其与中医证候相关性的研讨[J].辽宁中医杂志,2008(35)：859-860.
[62]宋玉洁.中医脾气虚证的现代研究近况与思考[J].山东中医药人学学报,25(3)：238-240.
[61]胡学军,黄穗平,张海燕.健脾理气方对功能性消化不良患者生存质量的影响[J].实用中医药杂志,2011,27(3)：148-149.
[64]郑虎占.中药现代研究与应用[M].北京：学苑出版社,1997：101.
[65]昆山,王秀琴,董一凡.现代临床中药学[M].北京：中国中医药出版,1998：177.
[66]苗明三主编,常见中药药理与临床[M].北京：中国中医药出版社,1997,83.
[67]王运平,邱世翠,李液清,等.补中益气汤对脾虚小鼠非特异性免疫和体液免疫的影响[J].滨州医学院学报,1998,21(1)：9.
[68]齐元富.汉方药对MRSA感染的疗效[J].国外医学·中医中药分册,2000,22(2)：76.